Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Global Market Opportunities and Competitive Landscape for CDMO
... the global CDMO market by service type, drug molecule type and end use. It also examines the regulatory policies, standards and inspection trends of the global CDMO markets. In addition, the competitive environment, significant rivals, ... Read More
-
Global Antiplatelet Market: Analysis By Drug Class (Adenosine Diphosphate Receptor Inhibitors, Irreversible Inhibitors Cyclooxygenase, and Other Drug Classes), By Route of Administration (Oral and Injectable), By Distribution Channel (Drug Stores, Hospital Pharmacies, and Online Stores), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2029
... By Region Size and Trends with Impact of COVID-19 and Forecast up to 2029 - Report Summary Report Metrics Details Years Considered 2019-2029 Base Year 2023 Forecast Period 2024-2029 Page Count 146 Units Referenced US ... Read More
-
Revenue Forecasts to (2031) and Analytics for the Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing (U.S.): Financial Benchmarks, Metrics, P&L, KPIs, NAIC 325412
... will save countless hours of research. Key Findings: Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing Industry (U.S.) to reach $312,882,043,584 by 2031. Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing Industry (U.S.), including Average EBITDA, Operating Ratios and ... Read More
-
Revenue Forecasts to (2031) and Analytics for the Pharmaceuticals and Druggists' Merchandise Distributors (U.S.): Financial Benchmarks, Metrics, P&L, KPIs, NAIC 424210
... save countless hours of research. Key Findings: Pharmaceuticals and Druggists' Merchandise Distributors Industry (U.S.) to reach $1,803,334,325,954 by 2031. Pharmaceuticals and Druggists' Merchandise Distributors Industry (U.S.), including Average EBITDA, Operating Ratios and Sales per Employee. ... Read More
-
Revenue Forecasts to (2031) and Analytics for the Pharmaceuticals, Medicines, Supplements and Drug Manufacturing (U.S.): Financial Benchmarks, Metrics, P&L, KPIs, NAIC 325400
... will save countless hours of research. Key Findings: Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.) to reach $387,074,915,562 by 2031. Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.), including Average EBITDA, Operating Ratios and ... Read More
-
Revenue Forecasts to (2031) and Analytics for the Drugs (Pharmaceuticals) and Druggists' Merchandise Distributors (U.S.): Financial Benchmarks, Metrics, P&L, KPIs, NAIC 424200
... will save countless hours of research. Key Findings: Drugs (Pharmaceuticals) and Druggists' Merchandise Distributors Industry (U.S.) to reach $1,803,334,325,954 by 2031. Drugs (Pharmaceuticals) and Druggists' Merchandise Distributors Industry (U.S.), including Average EBITDA, Operating Ratios and ... Read More
-
Global Pharmaceuticals & Medicine Manufacturing - Industry Market Research Report
... has provided a larger customer base for companies in the Global Pharmaceuticals and Medicine Manufacturing industry. Many manufacturers have also tapped into regional demand for pharmaceuticals that may differ from developed markets and have expanded ... Read More
-
Pharmaceutical Preparations Manufacturing in Ireland - Industry Market Research Report
... and generous research and development tax credits offered by the Irish state make the country a highly appealing location for multinational pharmaceutical manufacturers to base their European operations. Consequently, nine of the 10 largest pharmaceutical ... Read More
-
Pharmaceutical Contract Management Consulting in the US - Industry Market Research Report
... patents on blockbuster drugs, has stimulated the volume of research and development (R&D) work outsourced by generic pharmaceutical and biotechnology companies, promoting growth for consultants. The outbreak of COVID-19 led to growth for consultants as ... Read More
-
Vitamin, Nutritional Supplement & Other Health-Related Product Manufacturing
... Herbalife Nutrition, Nature's Bounty, and USANA (all based in the US), as well as Arkopharma (France), Nelsons (UK), Tong Ren Tang (China), and divisions of companies such as Pfizer and Procter & Gamble (both based ... Read More
-
Phase Transfer Catalyst Market: Global Market Size, Forecast, Insights, Segmentation, and Competitive Landscape with Impact of COVID-19 & Russia-Ukraine War
... 5.1% during 2025-2034. This report on global phase transfer catalyst market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. The report presents a clear picture of ... Read More
-
Pharmaceutical Grade Silica Gel
... reach US$184.5 Million by 2030, growing at a CAGR of 8.5% over the analysis period 2023-2030. Desiccant Application, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach ... Read More
-
Global Chlorhexidine Gluconate Product for Patient Skin Antisepsis Market Report, History and Forecast 2019-2030
... reach $ 780.46 million by 2030, at a CAGR of 3.64% during the forecast period of 2024 through 2030. North American market for Chlorhexidine Gluconate Product for Patient Skin Antisepsis was valued at $ 217.01 ... Read More
-
Impact of Covid-19 on Pharmaceuticals Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
... of Covid-19 on the pharmaceuticals market size was valued at USD 1,494.67 billion in 2021, and the market is now projected to grow from USD 1,585.05 billion in 2022 to USD 2,401.22 billion by 2029, ... Read More
-
Myelodysplastic Syndrome (MDS) Drugs
... reach US$4.1 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2023-2030. Immunomodulatory Drugs, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach ... Read More
-
Pharmaceutical Cartridges
... at a CAGR of 6.7% over the analysis period 2023-2030. Glass Material, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$2.0 Billion by the end of ... Read More
-
Native Collagen
... at a CAGR of 5.9% over the analysis period 2023-2030. Bovine Source, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$130.6 Million by the end of ... Read More
-
Pharmaceutical Analytical Testing Outsourcing
... reach US$16.3 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2023-2030. Bioanalytical Testing Service, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and ... Read More
-
Orphan Drugs
... at a CAGR of 11.9% over the analysis period 2023-2030. Biologic Drugs, one of the segments analyzed in the report, is expected to record a 12.7% CAGR and reach US$286.3 Billion by the end of ... Read More
-
Calcium Channel Blockers
... by 2030, growing at a CAGR of 6.1% over the analysis period 2023-2030. Dihydropyridine Drug Class, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$17.1 Billion ... Read More
-
Myeloproliferative Disorders Drugs
... by 2030, growing at a CAGR of 4.3% over the analysis period 2023-2030. Ph+ Chronic myelogenous leukemia (CML) Drugs, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and ... Read More
-
Nanocapsules
... of 6.3% over the analysis period 2023-2030. Oncology Therapy Area, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis ... Read More
-
Anticholinergic Drugs
... at a CAGR of 5.0% over the analysis period 2023-2030. Synthetic Compounds, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$6.6 Billion by the end of ... Read More
-
Sodium Alginate
... at a CAGR of 4.9% over the analysis period 2023-2030. Stabilizers Application, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$137.4 Million by the end of ... Read More
-
Sarcoma Drugs
... at a CAGR of 7.5% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$1.9 Billion by the end of ... Read More
Research Assistance
